Literature DB >> 25466598

ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.

Sha Li1, Rui-Xia Xu1, Yuan-Lin Guo1, Yan Zhang1, Cheng-Gang Zhu1, Jing Sun1, Jian-Jun Li2.   

Abstract

BACKGROUND AND AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9), a newly-identified member that plays an essential role in cholesterol homeostasis and holds decent promise for hyperlipidemia and coronary artery disease (CAD) treatment. However, the determining factors of PCSK9 are not well-characterized. It is well established that ABO blood group is associated with cholesterol metabolism. Therefore, the relationship between ABO blood groups and plasma PCSK9 level was examined. METHODS AND
RESULTS: A group of 507 consecutive patients undergoing diagnostic or interventional coronary angiography were enrolled in this cross-sectional study. The baseline clinical characteristics were collected, and the plasma PCSK9 levels were determined using ELISA. As a result, subjects of non-O type had higher levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), non high density lipoprotein cholesterol (NHDL-C), apolipoprotein B (apo B), and PCSK9 compared with that of O type (p < 0.05, all). PCSK9 levels were significantly and positively related to TC, LDL, NHDL-C, and apo B (r = 0.253, p < 0.001; r = 0.262, p < 0.001; r = 0.215, p < 0.001; r = 0.187, p < 0.001; respectively). Multivariable regression analysis revealed that ABO group was significantly and independently associated with PCSK9 level (β = 7.91, p = 0.009). Additionally, mediation analysis indicated that ≈8%-19% of the effect of ABO blood group on PCSK9 levels was mediated by TC, LDL-C or NHDL-C levels.
CONCLUSIONS: These data firstly suggested that the ABO blood group might be a significant determinant factor for plasma PCSK9 level. It is also possible that the observed association between PCSK9 and ABO blood group might be in part involved in their CAD susceptibility.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ABO blood group; Coronary artery disease; Lipid; Proprotein convertase subtilisin/kexin type 9

Mesh:

Substances:

Year:  2014        PMID: 25466598     DOI: 10.1016/j.numecd.2014.10.015

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  4 in total

1.  Impact of glucose and lipid markers on the correlation of calculated and enzymatic measured low-density lipoprotein cholesterol in diabetic patients with coronary artery disease.

Authors:  Qiu-Ting Dong; Ying Gao; Na-Qiong Wu; Yuan-Lin Guo; Cheng-Gang Zhu; Sha Li; Hui-Hui Liu; Ye-Xuan Cao; Hui-Wen Zhang; Xi Zhao; Geng Liu; Qian Dong; Jian-Jun Li
Journal:  J Clin Lab Anal       Date:  2018-01-30       Impact factor: 2.352

Review 2.  ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data.

Authors:  Jacques Le Pendu; Adrien Breiman; Jézabel Rocher; Michel Dion; Nathalie Ruvoën-Clouet
Journal:  Viruses       Date:  2021-01-22       Impact factor: 5.048

3.  Identification and replication of novel genetic variants of ABO gene to reduce the incidence of diseases and promote longevity by modulating lipid homeostasis.

Authors:  Xiaolin Ni; Chen Bai; Chao Nie; Liping Qi; Yifang Liu; Huiping Yuan; Xiaoquan Zhu; Liang Sun; Qi Zhou; Yan Li; Hefu Zhen; Huabing Su; Rongqiao Li; Rushu Lan; Guofang Pang; Yuan Lv; Wei Zhang; Fan Yang; Yao Yao; Chen Chen; Zhaoping Wang; Danni Gao; Nan Zhang; Shenqi Zhang; Li Zhang; Zhu Wu; Caiyou Hu; Yi Zeng; Ze Yang
Journal:  Aging (Albany NY)       Date:  2021-11-22       Impact factor: 5.682

4.  A phenome-wide association study of ABO blood groups.

Authors:  Shun Li; C M Schooling
Journal:  BMC Med       Date:  2020-11-17       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.